ExsoMed completed its second round of financing. Proceeds will support surgeon education and upcoming 2020 and early 2021 product launches.
The company's technologies for hand surgery include (shown above, left to right) INNATE™ for metacarpal fracture fixation and ARCPHIX™ and ARROWPHIX™ for distal interphalangeal joint fusion.
The INNATE intramedullary threaded nail recently surpassed the milestone of 5,000 metacarpal fractures treated.
ExsoMed previously raised $6.8 million in 2019.
"We are gratified by the market's enthusiasm for ExsoMed, not just from our individual investors, but also from our expanded distribution network and surgeon users," said Daniel Mickelsen, ExsoMed's Chief Operating and Financial Officer. "This influx of capital ensures that ExsoMed will support our rapid growth and continue to deliver innovation to the hand surgery market, all while creating value for our shareholders."